ReviewInternational journal of molecular sciences2025
In Vitro Culture, Genetic Transformation and the Production of Biopharmaceuticals in Microalgae.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microalgae represent a promising platform for the synthesis of recombinant proteins, particularly in the context of biopharmaceutical applications. Their unique combination of eukaryotic cellular machinery and prokaryotic-like simplicity offers several advantages, including the ability to perform complex post-translational modifications, rapid growth rates, and cost-effective culture conditions. Advances in genome sequencing, genetic engineering tools, and omics technologies have significantly enhanced the feasibility and efficiency of using microalgae for therapeutic protein production. These advancements, coupled with the development of well-established transformation methods and optimized vectors, have enabled the successful expression of various biopharmaceuticals, ranging from vaccines to enzymes. Here, the main stages and current status of the production of exogenic recombinant proteins dedicated to human therapy are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.